Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI
Abstract Purpose We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. Methods and materials 8 patients with GEP-NET were imaged u...
Gespeichert in:
| Veröffentlicht in: | European journal of radiology 2012-10, Vol.81 (10), p.2820-2825 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2825 |
|---|---|
| container_issue | 10 |
| container_start_page | 2820 |
| container_title | European journal of radiology |
| container_volume | 81 |
| creator | Giesel, F.L Kratochwil, C Mehndiratta, A Wulfert, S Moltz, J.H Zechmann, C.M Kauczor, H.U Haberkorn, U Ley, S |
| description | Abstract Purpose We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. Methods and materials 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. Results Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median −0.65 and −1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. Conclusion Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs. |
| doi_str_mv | 10.1016/j.ejrad.2011.11.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1034514747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0720048X11007832</els_id><sourcerecordid>1034514747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-220c20f48d77621c77ecb476e9ec07bd949e0a7ca3f6f4ef38e453c966442ca73</originalsourceid><addsrcrecordid>eNqFksFu1DAQhi1ERbeFJ0BCPnLJYjveODmAVIUWKrVaBEHiZnntCeuQ2IudgJaH4VlxdksP5YA0kuXR989o5h-EnlOypIQWr7oldEGZJSOULlMQIh6hBS0Fy4Rg4jFaEMFIRnj55RSdxdgRQla8Yk_QKWMsLwThC_S79sNOBRu9w77FDqbgwRmvg3WAx2nwARsYQY82EcoZrLcqKD1CsL_UITlF677it-vmolnX2YfLBluHtQ8B-iPw047blHBjUHHE4LbKaTC4bg71TML26fsvcPvx-ik6aVUf4dnde44-X1029fvsZv3uur64yTSnfMwYI5qRlpdGiIJRLQToDRcFVKCJ2JiKV0CU0Cpvi5ZDm5fAV7muioJzppXIz9HLY91d8N8niKMcbNTQ98qBn6KkJOcrygWf0fyI6uBjDNDKXbCDCvsEydkY2cmDMXI2RqZIxiTVi7sG02YAc6_560QCXh8BSGP-sBBk1BbmPdiQti-Nt_9p8OaBXvfWWa36b7CH2PkpuLRBSWVkkshP823Mp0FpUpc5y_8AXQC3RA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1034514747</pqid></control><display><type>article</type><title>Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Giesel, F.L ; Kratochwil, C ; Mehndiratta, A ; Wulfert, S ; Moltz, J.H ; Zechmann, C.M ; Kauczor, H.U ; Haberkorn, U ; Ley, S</creator><creatorcontrib>Giesel, F.L ; Kratochwil, C ; Mehndiratta, A ; Wulfert, S ; Moltz, J.H ; Zechmann, C.M ; Kauczor, H.U ; Haberkorn, U ; Ley, S</creatorcontrib><description>Abstract Purpose We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. Methods and materials 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. Results Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median −0.65 and −1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. Conclusion Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.</description><identifier>ISSN: 0720-048X</identifier><identifier>EISSN: 1872-7727</identifier><identifier>DOI: 10.1016/j.ejrad.2011.11.007</identifier><identifier>PMID: 22236704</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Comparison study ; Contrast enhanced CT ; Contrast enhanced MRI ; Contrast Media - administration & dosage ; Female ; Gadolinium DTPA - administration & dosage ; Gastroenteropancreatic neuroendocrine tumors ; Gd-EOB-DTPA ; Humans ; Indium Radioisotopes ; Iopamidol - administration & dosage ; Iopamidol - analogs & derivatives ; Magnetic Resonance Imaging - methods ; Male ; Metastatic liver lesions ; Neuroendocrine Tumors - diagnosis ; Octreotide - analogs & derivatives ; PET-CT ; Positron-Emission Tomography - methods ; Radiology ; Radiopharmaceuticals ; Reproducibility of Results ; Sensitivity and Specificity ; Statistics as Topic ; Tomography, X-Ray Computed - methods</subject><ispartof>European journal of radiology, 2012-10, Vol.81 (10), p.2820-2825</ispartof><rights>2011</rights><rights>Copyright © 2011. Published by Elsevier Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-220c20f48d77621c77ecb476e9ec07bd949e0a7ca3f6f4ef38e453c966442ca73</citedby><cites>FETCH-LOGICAL-c414t-220c20f48d77621c77ecb476e9ec07bd949e0a7ca3f6f4ef38e453c966442ca73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0720048X11007832$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22236704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giesel, F.L</creatorcontrib><creatorcontrib>Kratochwil, C</creatorcontrib><creatorcontrib>Mehndiratta, A</creatorcontrib><creatorcontrib>Wulfert, S</creatorcontrib><creatorcontrib>Moltz, J.H</creatorcontrib><creatorcontrib>Zechmann, C.M</creatorcontrib><creatorcontrib>Kauczor, H.U</creatorcontrib><creatorcontrib>Haberkorn, U</creatorcontrib><creatorcontrib>Ley, S</creatorcontrib><title>Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI</title><title>European journal of radiology</title><addtitle>Eur J Radiol</addtitle><description>Abstract Purpose We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. Methods and materials 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. Results Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median −0.65 and −1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. Conclusion Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.</description><subject>Comparison study</subject><subject>Contrast enhanced CT</subject><subject>Contrast enhanced MRI</subject><subject>Contrast Media - administration & dosage</subject><subject>Female</subject><subject>Gadolinium DTPA - administration & dosage</subject><subject>Gastroenteropancreatic neuroendocrine tumors</subject><subject>Gd-EOB-DTPA</subject><subject>Humans</subject><subject>Indium Radioisotopes</subject><subject>Iopamidol - administration & dosage</subject><subject>Iopamidol - analogs & derivatives</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Metastatic liver lesions</subject><subject>Neuroendocrine Tumors - diagnosis</subject><subject>Octreotide - analogs & derivatives</subject><subject>PET-CT</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Statistics as Topic</subject><subject>Tomography, X-Ray Computed - methods</subject><issn>0720-048X</issn><issn>1872-7727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhi1ERbeFJ0BCPnLJYjveODmAVIUWKrVaBEHiZnntCeuQ2IudgJaH4VlxdksP5YA0kuXR989o5h-EnlOypIQWr7oldEGZJSOULlMQIh6hBS0Fy4Rg4jFaEMFIRnj55RSdxdgRQla8Yk_QKWMsLwThC_S79sNOBRu9w77FDqbgwRmvg3WAx2nwARsYQY82EcoZrLcqKD1CsL_UITlF677it-vmolnX2YfLBluHtQ8B-iPw047blHBjUHHE4LbKaTC4bg71TML26fsvcPvx-ik6aVUf4dnde44-X1029fvsZv3uur64yTSnfMwYI5qRlpdGiIJRLQToDRcFVKCJ2JiKV0CU0Cpvi5ZDm5fAV7muioJzppXIz9HLY91d8N8niKMcbNTQ98qBn6KkJOcrygWf0fyI6uBjDNDKXbCDCvsEydkY2cmDMXI2RqZIxiTVi7sG02YAc6_560QCXh8BSGP-sBBk1BbmPdiQti-Nt_9p8OaBXvfWWa36b7CH2PkpuLRBSWVkkshP823Mp0FpUpc5y_8AXQC3RA</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Giesel, F.L</creator><creator>Kratochwil, C</creator><creator>Mehndiratta, A</creator><creator>Wulfert, S</creator><creator>Moltz, J.H</creator><creator>Zechmann, C.M</creator><creator>Kauczor, H.U</creator><creator>Haberkorn, U</creator><creator>Ley, S</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI</title><author>Giesel, F.L ; Kratochwil, C ; Mehndiratta, A ; Wulfert, S ; Moltz, J.H ; Zechmann, C.M ; Kauczor, H.U ; Haberkorn, U ; Ley, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-220c20f48d77621c77ecb476e9ec07bd949e0a7ca3f6f4ef38e453c966442ca73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Comparison study</topic><topic>Contrast enhanced CT</topic><topic>Contrast enhanced MRI</topic><topic>Contrast Media - administration & dosage</topic><topic>Female</topic><topic>Gadolinium DTPA - administration & dosage</topic><topic>Gastroenteropancreatic neuroendocrine tumors</topic><topic>Gd-EOB-DTPA</topic><topic>Humans</topic><topic>Indium Radioisotopes</topic><topic>Iopamidol - administration & dosage</topic><topic>Iopamidol - analogs & derivatives</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Metastatic liver lesions</topic><topic>Neuroendocrine Tumors - diagnosis</topic><topic>Octreotide - analogs & derivatives</topic><topic>PET-CT</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Statistics as Topic</topic><topic>Tomography, X-Ray Computed - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giesel, F.L</creatorcontrib><creatorcontrib>Kratochwil, C</creatorcontrib><creatorcontrib>Mehndiratta, A</creatorcontrib><creatorcontrib>Wulfert, S</creatorcontrib><creatorcontrib>Moltz, J.H</creatorcontrib><creatorcontrib>Zechmann, C.M</creatorcontrib><creatorcontrib>Kauczor, H.U</creatorcontrib><creatorcontrib>Haberkorn, U</creatorcontrib><creatorcontrib>Ley, S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giesel, F.L</au><au>Kratochwil, C</au><au>Mehndiratta, A</au><au>Wulfert, S</au><au>Moltz, J.H</au><au>Zechmann, C.M</au><au>Kauczor, H.U</au><au>Haberkorn, U</au><au>Ley, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI</atitle><jtitle>European journal of radiology</jtitle><addtitle>Eur J Radiol</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>81</volume><issue>10</issue><spage>2820</spage><epage>2825</epage><pages>2820-2825</pages><issn>0720-048X</issn><eissn>1872-7727</eissn><abstract>Abstract Purpose We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET. Methods and materials 8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists. Results Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median −0.65 and −1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively. Conclusion Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>22236704</pmid><doi>10.1016/j.ejrad.2011.11.007</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0720-048X |
| ispartof | European journal of radiology, 2012-10, Vol.81 (10), p.2820-2825 |
| issn | 0720-048X 1872-7727 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1034514747 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Comparison study Contrast enhanced CT Contrast enhanced MRI Contrast Media - administration & dosage Female Gadolinium DTPA - administration & dosage Gastroenteropancreatic neuroendocrine tumors Gd-EOB-DTPA Humans Indium Radioisotopes Iopamidol - administration & dosage Iopamidol - analogs & derivatives Magnetic Resonance Imaging - methods Male Metastatic liver lesions Neuroendocrine Tumors - diagnosis Octreotide - analogs & derivatives PET-CT Positron-Emission Tomography - methods Radiology Radiopharmaceuticals Reproducibility of Results Sensitivity and Specificity Statistics as Topic Tomography, X-Ray Computed - methods |
| title | Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A00%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20neuroendocrine%20tumor%20detection%20and%20characterization%20using%20DOTATOC-PET%20in%20correlation%20with%20contrast%20enhanced%20CT%20and%20delayed%20contrast%20enhanced%20MRI&rft.jtitle=European%20journal%20of%20radiology&rft.au=Giesel,%20F.L&rft.date=2012-10-01&rft.volume=81&rft.issue=10&rft.spage=2820&rft.epage=2825&rft.pages=2820-2825&rft.issn=0720-048X&rft.eissn=1872-7727&rft_id=info:doi/10.1016/j.ejrad.2011.11.007&rft_dat=%3Cproquest_cross%3E1034514747%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1034514747&rft_id=info:pmid/22236704&rft_els_id=S0720048X11007832&rfr_iscdi=true |